Daniel Thomas
Academic Appointments
- Postdoctoral Research fellow, Stanford Cancer Institute
Key Documents
Contact Information
- Academic Offices
Personal Information Email
Professional Overview
Honors and Awards
- CJ Martin Fellowship, National Health and Medical Research Council of Australia (2011)
- Albert Baikie Memorial Medal, Haematology Society of Australia & New Zealand (2007)
- HOTT Haematology/Oncology Targetted Therapy Fellowship, Haematology Society of Australia & New Zealand/COSA/Roche/COGA (2010)
- National FRACP Adult Medicine Research Award, Royal Australasian College of Physicians (2008)
- John Chalmers Prize for Best Medical Research Presentation, Royal Australasian College of Physicians (2007)
- Outstanding Research Presentation Prize, New Directions in Leukaemia Conference (2010)
Professional Education
| Ph D: | University of Adelaide, Leukemia Stem Cells:- Signalling and Therapeutic Targets (2012) |
| FRACP: | Fellow of the Royal Australasian College of Physicians, Hematology (2007) |
| FRCPA: | Fellow of the Royal College of Pathologists of Australasia, Hematology (2007) |
| Bachelor of Science: | University Of Adelaide (1998) |
| B of Medicine and B of Surgery: | University Of Adelaide (2000) |
Stanford Advisors
| Ravindra Majeti: | Postdoctoral Research Mentor |
Scientific Focus
Current Research Interests
Whilst cancer is first a disease of unregulated cell proliferation, a small proportion of cells within a tumour are paradoxically in a relative state of quiescence. These chemotherapy-resistant cells are the likely culprits responsible for relapse but the signalling events that control this state are unknown. By studying purified populations of cancer stem cells derived from patients with acute myeloid leukemia my work is focused on defining novel targets for future therapy.
Publications
- Protein Kinase Activity of Phosphoinositide 3-Kinase Regulates Cytokine-Dependent Cell Survival PLOS Biology. 2013; (3): e1001515
- Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood. 2009; (23): 4859-70
- Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009; (1): 31-42
- The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood. 2009; (7): 1289-98
- Phosphorylation of Serine 779 in Fibroblast Growth Factor Receptor 1 and 2 by Protein Kinase C epsilon regulates Ras/MAP kinase signaling and neuronal differentiation. J Biol Chem. 2013
- Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res. 2010; (13): 5438-47
Help
Trial Administration